Hair Depigmentation is a Biological Readout for Pharmacological Inhibition of KIT in Mice and Humans

Journal of Pharmacology and Experimental Therapeutics

Volumn 307, Issue 2, 2003, Pages 476-480

  Moss, Katherine G ^a   Toner, Guy C ^b   Cherrington, Julie M ^a   Mendel, Dirk B ^a   Laird, A Douglas ^a,b  

^a SUGEN INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; FLT3 LIGAND; KIT RECEPTOR TYROSINE KINASE; NEUTRALIZING ANTIBODY; NEUTRALIZING MONOCLONAL ANTIBODY ACK2; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CELL FUNCTION; CELL MATURATION; CELL SURVIVAL; CONTROLLED STUDY; DEPIGMENTATION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; FEMALE; HAIR COLOR; HAIR FOLLICLE; HAIR GROWTH; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MELANOCYTE; MOUSE; MOUSE STRAIN; NONHUMAN; PIGMENT DISORDER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN STRUCTURE;

ANIMALS; ENZYME INHIBITORS; FEMALE; HAIR COLOR; HUMANS; INDOLES; MICE; MICE, INBRED C57BL; PROTO-ONCOGENE PROTEINS C-KIT; PYRROLES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 0142241307     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.052530     Document Type: Article

References (31)

1. Abrams TJ, Lee LB, Murray LJ, Pryer NK, and Cherrington JM (2003) SU11248 inhibits KIT and PDGFRβ in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471-478.
2. Botchkareva NV, Khlgatian M, Longley BJ, Botchkarev VA, and Gilchrest BA (2001) SCF/c-kit signaling is required for cyclic regeneration of the hair pigmentation unit. FASEB J 15:645-658.
3. Chabot B, Stephenson DA, Chapman VM, Besmer P, and Bernstein A (1988) The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature (Lond) 335:88-89.
4. Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, Rahman A, Chen G, Staten A, Griebel D, et al. (2002) Approval summary: imatinib mesylate in the treatment of metastatic and/or resectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8:3034-3038.
5. Etienne G, Cony-Makhoul P, and Mahon FX (2002) Imatinib mesylate and gray hair. N Engl J Med 347:446.
6. Halaban R and Moellmann G (1993) White mutants in mice shedding light on humans. J Investig Dermatol 100:176S-185S.
7. Heinrich MC, Blanke CD, Druker BJ, and Corless CL (2002) Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20:1692-1703.
8. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, et al. (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science (Wash DC) 279:577-580.
9. Krishnaswamy G, Kelley J, Johnson D, Youngberg G, Stone W, Huang SK, Bieber J, and Chi DS (2001) The human mast cell: functions in physiology and disease. Front Biosci 6:D1109-D1127.
10. Marklund S, Kijas J, Rodriguez-Martinez H, Ronnstrand L, Funa K, Moller M, Lange D, Edfors-Lilja I, and Andersson L (1998) Molecular basis for the dominant white phenotype in the domestic pig. Genome Res 8:826-833.
11. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, et al. (2003) In vivo anti-tumor activity of SU11248, a novel tyrosine kinase inhibitor targeting VEGF and PDGF receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337.
12. Nishikawa S, Kusakabe M, Yoshinaga K, Ogawa M, Hayashi S, Kunisada T, Era T, and Sakakura T (1991) In utero manipulation of coat color formation by a monoclonal anti-c-kit antibody: two distinct waves of c-kit-dependency during melanocyte development. EMBO J 10:2111-2118.
13. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, et al. (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597-3605.
14. Paus R and Cotsarelis G (1999) The biology of hair follicles. N Engl J Med 341:491-497.
15. Paus R, Stenn KS, and Link RE (1990) Telogen skin contains an inhibitor of hair growth. Br J Dermatol 122:777-784.
16. Perez-Losada J, Sanchez-Martin M, Rodriguez-Garcia A, Sanchez ML, Orfao A, Flores T, and Sanchez-Garcia I (2002) Zinc-finger transcription factor Slug contributes to the function of the stem cell factor c-kit signaling pathway. Blood 100:1274-1286.
17. Raanani P, Goldman JM, and Ben-Bassat I (2002) Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571. J Clin Oncol 20:869-870.
18. Raymond E, Faivre S, Vera K, Delbaldo C, Robert C, Spatz A, Bello C, Brega N, Scigalla P, and Armand J-P (2003) Final results of a phase I and pharmacokinetic study of SU11248, a novel multi-target tyrosine kinase inhibitor, in patients with advanced cancers. American Society of Clinical Oncology Annual Meeting, Abstract 769.
19. Richards KA, Fukai K, Oiso N, and Paller AS (2001) A novel KIT mutation results in piebaldism with progressive depigmentation. J Am Acad Dermatol 44:288-292.
20. Robert C, Spatz A, Faivre S, Armand J-P, and Raymond E (2003) Tyrosine kinase inhibition and grey hair. Lancet 361:1056.
21. Sarna JR, Dyck RH, and Whishaw IQ (2000) The Dalila effect: C57BL6 mice barber whiskers by plucking. Behav Brain Res 108:39-45.
22. Scott G, Leopardi S, Printup S, and Madden BC (2002) Filopodia are conduits for melanosome transfer to keratinocytes. J Cell Sci 1:1441-1451.
23. Stephenson DA, Lee KH, Nagle DL, Yen CH, Morrow A, Miller D, Chapman VM, and Bucan M (1994) Mouse rump-white mutation associated with an inversion of chromosome 5. Mamm Genome 5:342-348.
24. Tobin DJ, Slominski A, Botchkarev V, and Paus R (1999) The fate of hair follicle melanocytes during the hair growth cycle. J Investig Dermatol Symp Proc 4:323-332.
25. Toner GC, Mitchell PL, De Boer R, Gibbs P, Hicks RM. Scott AM, McArthur G, Brega N, Massimini G, and Scigalla P (2003) PET imaging study of SU11248 in patients with advanced malignancies. American Society of Clinical Oncology Annual Meeting, Abstract 767.
26. Turner AM, Zsebo KM, Martin F, Jacobsen FW, Bennett LG, and Broudy VC (1992) Nonhematopoietic tumor cell lines express stem cell factor and display c-kit receptors. Blood 80:374-381.
27. Washington C, Eli M, Bello C, Schaaf L, Polasek E, Tan LH, Scigalla P, and Sarapa N (2003) The effect of ketoconazole (KETO), a potent CYP3A4 inhibitor, on SU011248 pharmacokinetics (PK) in Caucasian and Asian healthy subjects. American Society of Clinical Oncology Annual Meeting, Abstract 553.
28. Wu M, Hemesath TJ, Takemoto CM, Horstmann MA, Wells AG, Price ER, Fisher DZ, and Fisher DE (2000) c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. Genes Dev 14:301-312.
29. Yoshida H, Kunisada T, Kusakabe M, Nishikawa S, and Nishikawa SI (1996) Distinct stages of melanocyte differentiation revealed by analysis of nonuniform pigmentation patterns. Development 122:1207-1214.
30. Yoshida H, Takakura N, Kataoka H, Kunisada T, Okamura H, and Nishikawa SI (1997) Stepwise requirement of c-kit tyrosine kinase in mouse ovarian follicle development. Dev Biol 184:122-137.
31. Zsebo KM, Williams DA, Geissler EN, Broudy VC, Martin FH, Atkins HL, Hsu RY, Birkett NC, Okino KH, and Murdock DC (1990) Stem cell factor is encoded at the S1 locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 63:213-224.